Risk for COVID-19 Vulnerability in Patients with Inflammatory Bowel Disease: Assessing Alterations in ACE2 and...

Area of Science:

• Gastroenterology
• Virology
• Enzymology

Background:

• Chronic inflammatory conditions, such as inflammatory bowel disease (IBD), are associated with dysregulated serine proteases.
• Transmembrane serine protease 2 (TMPRSS2) and angiotensin converting enzyme 2 (ACE2) are key enzymes in SARS-CoV-2 cellular entry.
• The role of these enzymes in gastrointestinal symptoms of COVID-19 and their interplay in IBD requires further investigation.

Purpose of the Study:

• To explore the interplay between ACE2 and TMPRSS2 in inflammatory bowel disease (IBD).
• To investigate the potential role of altered ACE2 and TMPRSS2 expression in SARS-CoV-2 gastrointestinal manifestations.
• To examine methodological approaches for assessing protease alterations and infection susceptibility.

Main Methods:

• Review of existing literature on ACE2 and TMPRSS2 in IBD and SARS-CoV-2 infection.
• Analysis of the enzymatic forms (zymogen vs. active) and cleavage of TMPRSS2 and ACE2.
• Discussion of the implications of soluble ACE2 fragments as decoys.

Main Results:

• Altered expression of ACE2 and TMPRSS2 may contribute to gastrointestinal symptoms in COVID-19 patients with IBD.
• TMPRSS2 exists in both inactive (zymogen) and active forms, influencing its role in viral entry.
• Soluble ACE2 may act as a decoy, potentially mitigating viral interaction with membrane-bound ACE2.

Conclusions:

• The interplay between ACE2 and TMPRSS2 is crucial in the context of IBD and SARS-CoV-2 infection.
• Understanding the differential expression and cleavage of ACE2 and TMPRSS2 is vital for assessing COVID-19 susceptibility.
• Further research is needed to elucidate the precise mechanisms linking these proteases to gastrointestinal pathology in IBD patients.